SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (579)1/9/2002 4:15:13 PM
From: tuck  Read Replies (2) of 1005
 
Nigel,

>>how many available chemistry companies are left out there?<<

Since you asked, the two available public ones I can think of are DPII -- already mentioned as a munch candidate by the press -- and EBIO.

>>MADISON, Wis.--(BUSINESS WIRE)--Jan. 9, 2002--Bruker AXS Inc. (Nasdaq: BAXS - news) today announced that the underwriters of its initial public offering have exercised their over-allotment option to purchase an additional 1,350,000 shares of the common stock of Bruker AXS at $6.50 per share for a total of approximately $8.2 million, after underwriters' discounts and commissions. This exercise and purchase by the underwriters will bring Bruker AXS Inc.'s initial public offering to 10,350,000 shares for approximately $62.7 million, after underwriters' discounts and commissions.

UBS Warburg LLC was bookrunning manager and, along with Thomas Weisel Partners LLC, co-lead manager of the offering. CIBC World Markets, SG Cowen and Robert W. Baird & Co. were the co-managers.<<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext